Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Gefapixant in two randomised dose-escalation studies in chronic cough

Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal 2020 55: 1901615; DOI: 10.1183/13993003.01615-2019
Jaclyn A. Smith
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jaclyn A. Smith
Michael M. Kitt
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Butera
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Smith
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jacky.smith@manchester.ac.uk
Yuping Li
3GetStat Solutions, LLC, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi Jin Xu
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberley Holt
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shilpi Sen
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mandel R. Sher
4Center for Cough, Largo, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony P. Ford
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background and objectives Gefapixant has previously demonstrated efficacy in the treatment of refractory chronic cough at a high daily dose. The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough using a dose-escalation approach.

Materials and methods Two randomised, double-blind, placebo-controlled, crossover, dose-escalation studies recruited participants with refractory chronic cough. Patients were assigned to receive ascending doses of gefapixant (study 1: 50–200 mg, study 2: 7.5–50 mg) or placebo for 16 days, then crossed-over after washout. The primary end-point was awake cough frequency assessed using a 24-h ambulatory cough monitor at baseline and on day 4 of each dose. Patient-reported outcomes included a cough severity visual analogue scale and the cough severity diary.

Results In clinical studies, gefapixant doses ≥30 mg produced maximal improvements in cough frequency compared with placebo (p<0.05); reported cough severity measures improved at similar doses. Taste disturbance exhibited a different relationship with dose, apparently maximal at doses ≥150 mg.

Conclusions P2X3 antagonism with gefapixant demonstrates anti-tussive efficacy and improved tolerability at lower doses than previously investigated. Studies of longer duration are warranted.

Abstract

Patients with refractory chronic cough had significant reductions in coughing with lower doses of gefapixant than previously evaluated demonstrating efficacy and improved tolerability http://bit.ly/2Rg3q2t

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This study is registered at www.clinicaltrials.gov with identifier number NCT02349425 and on the EU Clinical Trials Register (EudraCT Number: 2015-000474-35) Data availability: the data sharing policy of Merck Sharp and Dohme Corp. (a subsidiary of Merck and Co., Inc., Kenilworth, NJ, USA), including restrictions, is available at http://engagezone.msd.com/ds_documentation.php. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.

  • Author contributions: J.A. Smith: conception, design or planning of the study, analysis of data, interpretation of results, drafting of the manuscript, critical review and revision of the manuscript. M.M. Kitt: conception, design or planning of the study, analysis of data, interpretation of results, critical review and revision of the manuscript. P. Butera: conception, design or planning of the study, acquisition of data, critical review and revision of the manuscript. S.A. Smith: analysis of data, critical review and revision of the manuscript. Y. Li: analysis of data, interpretation of results, critical review and revision of the manuscript. Z.J. Xu: analysis of data, critical review and revision of the manuscript. K. Holt: analysis of data, critical review and revision of the manuscript. S. Sen: analysis of data, drafting of the manuscript. M.R. Sher: acquisition of data, interpretation of results, critical review and revision of the manuscript. A.P. Ford: conception, design or planning of the study, interpretation of results, drafting of the manuscript, critical review and revision of the manuscript.

  • Conflict of interest: J.A. Smith reports research grants and personal fees for consultancy and advisory board work from Merck Inc., during the conduct of the study; research grants and personal fees for consultancy and advisory board work from GlaxoSmithKline, research grants and personal fees for consultancy from NeRRe Pharmaceuticals, Menlo, Bayer and Axalbion, personal fees for consultancy from Boehringer Ingleheim, Genentech, Neomed, Chiesi, Bellus and AstraZeneca, non-financial support (equipment provision) from Vitalograph, research grants from Afferent, outside the submitted work; in addition, has a patent “A method for generating output data” licensed.

  • Conflict of interest: M.M. Kitt was an employee of Merck/Afferent, during the conduct of the study.

  • Conflict of interest: P. Butera was an employee of Afferent Pharmaceuticals, Inc., during the conduct of the study.

  • Conflict of interest: S.A. Smith reports personal fees for consultancy from Afferent Pharmaceuticals, during the conduct of the study.

  • Conflict of interest: Y. Li reports personal fees for statistical work from Afferent/Merck and Co., Inc, during the conduct of the study.

  • Conflict of interest: Z.J Xu has nothing to disclose.

  • Conflict of interest: K. Holt has nothing to disclose.

  • Conflict of interest: S. Sen has nothing to disclose.

  • Conflict of interest: M.R. Sher reports personal fees from Afferent and Merck, during the conduct of the study; and is consultant to Bellus, Bayer, NeRRe with clinical studies with Menlo and NeRRe.

  • Conflict of interest: A.P. Ford was an employee of Merck/Afferent, during the conduct of the study.

  • Support statement: This study was supported by funding from Afferent Pharmaceuticals Inc., which was acquired by Merck Sharp and Dohme Corp., a subsidiary of Merck and Co., Inc., Kenilworth, NJ, USA. J.A. Smith is funded by the Manchester Biomedical Research Centre, a Wellcome Investigator award and is an NIHR Senior Investigator. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received August 13, 2019.
  • Accepted December 19, 2019.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 3 Table of Contents
European Respiratory Journal: 55 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gefapixant in two randomised dose-escalation studies in chronic cough
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal Mar 2020, 55 (3) 1901615; DOI: 10.1183/13993003.01615-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal Mar 2020, 55 (3) 1901615; DOI: 10.1183/13993003.01615-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • EmPHasis-10 as a measure of quality of life in PAH
  • EmPHasis-10 health-related quality of life score predicts outcomes in PAH
  • Periostin and airway epithelial function in asthma
Show more Original Articles

Cough

  • Effect of pain conditioning on experimentally evoked cough
  • Altered neural activity in cough suppression networks in smokers
Show more Cough

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society